Skip to Content

Tau Therapeutics LLC to Present Posters at AACR on T-Type Calcium Channel Inhibitors and Interlaced Therapy

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Mar 29, 2012 - Tau Therapeutics LLC announced today that its academic collaborators will present three posters at the American Association of Cancer Research's 103rd annual meeting in Chicago, Illinois, March 31 – April 4, 2012. The posters will highlight the company's non-toxic, selective T-type calcium channel inhibitors for the treatment of brain and breast cancers. The company's approach, called Interlaced Therapy™, capitalizes on the central role of calcium influx through T-type calcium channels during cancer cell growth. In pre-clinical studies, T-type calcium channel blockade with Tau's drugs arrests tumor cells at their most vulnerable metabolic point in the cell cycle, uniquely amplifying the effects of conventional therapies and overcoming drug resistance.

“The data to be presented at AACR provides further validation for our mechanism of action – the T-type calcium channel – and our novel method – Interlaced Therapy™,” said Dr. Lloyd Gray, Chief Scientific Officer of Tau Therapeutics LLC. “We are excited to have more data that demonstrate the potential for our drugs to have real impact on the lives of cancer patients.”

The three posters to be presented are:

Dr. Stephen Keir of Duke University will present his late-breaking results entitled “Mibefradil, a Novel Therapy for Glioblastoma: An Interlaced Therapy Approach.”

Dr. Jaroslaw Dziegielewski of the University of Virginia will present his late-breaking results entitled “Targeting T-type Calcium Channels Induces the Extrinsic Apoptotic Pathway and Sensitizes Glioblastoma Cancer Cells to Radio- and Chemotherapy.”

Dr. Ming Li of Tulane University will present his results entitled “Mibefradil Increases Paclitaxel's Effect on MCF-7 Cell Proliferation In Vitro and In Vivo.”

About Tau Therapeutics LLC

Tau Therapeutics is a clinical stage company developing oncology drugs for solid tumors that selectively inhibit the T-type calcium channel. Tau Therapeutics is a private company based in Charlottesville, VA.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Tau Therapeutics LLC disclaims any intent or obligation to update forward-looking statements, except as required by law.

Contact: Tau Therapeutics LLC
Andrew Krouse, 434-974-6969


Posted: March 2012